ZEALAND PHARMA A/S (22Z.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:22Z - DK0060257814 - Common Stock
22Z.DE Key Statistics, Chart & Performance
The current stock price of 22Z.DE is 71.92 EUR. In the past month the price increased by 15.7%.
22Z.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.11 | 49.10B | ||
| 1AE.DE | ARGENX SE | 74.13 | 49.11B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.87B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.70B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.69B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.31 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 822.55M | ||
| PHIL.MI | PHILOGEN SPA | 20.96 | 698.84M | ||
| IVA.PA | INVENTIVA SA | N/A | 541.14M | ||
| ALCLS.PA | CELLECTIS | N/A | 440.93M | ||
| FYB.DE | FORMYCON AG | N/A | 438.22M |
Related stock screener links
About 22Z.DE
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Company Info
ZEALAND PHARMA A/S
Sydmarken 11
Soeborg DK
Employees: 424
Phone: 4588773600
ZEALAND PHARMA A/S / 22Z.DE FAQ
What does ZEALAND PHARMA A/S do?
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
What is the stock price of ZEALAND PHARMA A/S today?
The current stock price of 22Z.DE is 71.92 EUR. The price increased by 3.19% in the last trading session.
Does 22Z stock pay dividends?
22Z.DE does not pay a dividend.
What is the ChartMill rating of ZEALAND PHARMA A/S stock?
22Z.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the employee count for 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) currently has 424 employees.
Can you provide the market cap for ZEALAND PHARMA A/S?
ZEALAND PHARMA A/S (22Z.DE) has a market capitalization of 3.32B EUR. This makes 22Z.DE a Mid Cap stock.
22Z.DE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to 22Z.DE.
22Z.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE. 22Z.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
22Z.DE Financial Highlights
Over the last trailing twelve months 22Z.DE reported a non-GAAP Earnings per Share(EPS) of 12.45. The EPS increased by 661.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 71.47% | ||
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| Debt/Equity | 0.03 |
22Z.DE Forecast & Estimates
25 analysts have analysed 22Z.DE and the average price target is 104.6 EUR. This implies a price increase of 45.44% is expected in the next year compared to the current price of 71.92.
For the next year, analysts expect an EPS growth of 652.64% and a revenue growth 11614.8% for 22Z.DE